-
公开(公告)号：EP2999484B1
公开(公告)日：2019-09-11
申请号：EP14732752.2
申请日：2014-05-23
-
公开(公告)号：EP3218722A1
公开(公告)日：2017-09-20
申请号：EP15802276.4
申请日：2015-11-13
CPC分类号： G01N33/6848 , C12Q1/34 , G01N33/6893 , G01N2400/40 , G01N2560/00 , G01N2800/042 , G01N2800/52
摘要： Detecting glycosaminoglycans (GAGs) and/or determining the level of one or more glycosaminoglycans can be useful, e.g., in identifying or monitoring various medical conditions, the status of patients having various medical conditions, and/or the response to treatment of individuals having various medical conditions. The present invention provides methods for detecting glycosaminoglycans and/or determining the level of glycosaminoglycans through the use of, e.g., mass spectrometry.
摘要翻译： 检测糖胺聚糖（GAG）和/或确定一种或多种糖胺聚糖的水平可用于例如识别或监测各种医疗状况，患有各种医疗状况的患者的状态和/或对具有各种 医疗条件。 本发明提供了通过使用例如质谱法检测糖胺聚糖和/或确定糖胺聚糖水平的方法。
-
3.发明公开ANTI-CCL2 AND ANTI-LOXL2 COMBINATION THERAPY FOR TREATMENT OF SCLERODERMA 审中-公开ANTI-CCL2-和抗LOXL2联合治疗硬皮病的治疗
公开(公告)号：EP2999484A1
公开(公告)日：2016-03-30
申请号：EP14732752.2
申请日：2014-05-23
发明人： MARTINI, Paolo G.V. , NATARAJAN, Madhusudan , HASLETT, Patrick Anthony John , SEYMOUR, Albert Barnes
CPC分类号： C07K16/40 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/24 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/626 , C07K2317/92
摘要： The present invention provides, among other things, bi-specific molecules including, but not limited to, antibodies, fynomers, aptamers, fuproteins, and protein binding domains that bind both CCL2 and LOXL2 and uses thereof, in particular, for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions. In some embodiments, the present invention further provides methods and compositions for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions based on the combination of mono-specific anti-CCL2 and anti-LOXL2 molecules.
-
-
搜索结果
3 条记录 (耗时 0.019 秒)
